{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:38:20Z","timestamp":1787985500033,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report our experience with the use of intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). A retrospective review was performed on 138 consecutive infants screened at a single centre over 18 months. Intravitreal ranibizumab was offered in selected cases requiring treatment, such as aggressive posterior ROP or poor mydriasis. 2 eyes of 1 infant received intravitreal ranibizumab alone and 8 eyes of 5 infants received combined intravitreal ranibizumab and laser therapy. 3 out of 8 eyes treated initially with intravitreal ranibizumab monotherapy had persistent disease requiring laser therapy, and 3 out of 5 eyes with initial regression suffered disease recurrence at a mean of 7.6 weeks post-injection. 2 eyes treated first with laser followed by intravitreal ranibizumab had disease regression without recurrence. Our cohort demonstrate a significant rate of persistent disease and recurrence in ROP eyes treated initially with intravitreal ranibizumab monotherapy, which is greater and earlier than that reported for intravitreal bevacizumab in the BEAT-ROP study. Intravitreal ranibizumab may be useful as an initial treatment in selected cases of ROP when laser therapy as first line is suboptimal. However, close monitoring is important and adjunctive laser therapy may subsequently be needed in a majority of cases.<\/jats:p>","DOI":"10.1038\/srep27082","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T05:54:25Z","timestamp":1464933265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy"],"prefix":"10.1038","volume":"6","author":[{"given":"Joyce J. T.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol P. S.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline K. M.","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L. M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K. Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie W. Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C. S.","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"BFsrep27082_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","volume":"74","author":"H Blencowe","year":"2013","unstructured":"Blencowe, H., Lawn, J. E., Vazquez, T., Fielder, A. & Gilbert, C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr. Res. 74 Suppl 1, 35\u201349 (2013).","journal-title":"Pediatr. Res."},{"key":"BFsrep27082_CR2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1542\/peds.2004-1309","volume":"115","author":"BA Darlow","year":"2005","unstructured":"Darlow, B. A. et al. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 115, 990\u20136 (2005).","journal-title":"Pediatrics"},{"key":"BFsrep27082_CR3","doi-asserted-by":"publisher","first-page":"e1483","DOI":"10.1542\/peds.2009-2218","volume":"125","author":"ML Chen","year":"2010","unstructured":"Chen, M. L., Guo, L., Smith, L. E. H., Dammann, C. E. L. & Dammann, O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics 125, e1483\u201392 (2010).","journal-title":"Pediatrics"},{"key":"BFsrep27082_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1542\/peds.112.5.1016","volume":"112","author":"A Hellstr\u00f6m","year":"2003","unstructured":"Hellstr\u00f6m, A. et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 112, 1016\u201320 (2003).","journal-title":"Pediatrics"},{"key":"BFsrep27082_CR5","doi-asserted-by":"publisher","first-page":"9091","DOI":"10.1038\/srep09091","volume":"5","author":"SCL Au","year":"2015","unstructured":"Au, S. C. L., Tang, S.-M., Rong, S.-S., Chen, L.-J. & Yam, J. C. S. Association between hyperglycemia and retinopathy of prematurity: a systemic review and meta-analysis. Sci. Rep. 5, 9091 (2015).","journal-title":"Sci. Rep."},{"key":"BFsrep27082_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.jp.7211420","volume":"26","author":"P Manzoni","year":"2006","unstructured":"Manzoni, P. et al. Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. J. Perinatol. 26, 23\u201330 (2006).","journal-title":"J. Perinatol."},{"key":"BFsrep27082_CR7","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/j.1651-2227.2010.01973.x","volume":"99","author":"A Leviton","year":"2010","unstructured":"Leviton, A. et al. The clustering of disorders in infants born before the 28th week of gestation. Acta Paediatr. 99, 1795\u2013800 (2010).","journal-title":"Acta Paediatr."},{"key":"BFsrep27082_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10792-014-9956-2","volume":"35","author":"GSK Yau","year":"2015","unstructured":"Yau, G. S. K. et al. Incidence and risk factors for retinopathy of prematurity in extreme low birth weight Chinese infants. Int. Ophthalmol. 35, 365\u201373 (2015).","journal-title":"Int. Ophthalmol."},{"key":"BFsrep27082_CR9","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1097\/MD.0000000000000867","volume":"94","author":"GSK Yau","year":"2015","unstructured":"Yau, G. S. K. et al. Incidence and risk factors for retinopathy of prematurity in multiple gestations: a Chinese population study. Medicine (Baltimore). 94, e867 (2015).","journal-title":"Medicine (Baltimore)."},{"key":"BFsrep27082_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m, A., Smith, L. E. & Dammann, O. Retinopathy of prematurity. Lancet 382, 1445\u20131457 (2013).","journal-title":"Lancet"},{"key":"BFsrep27082_CR11","doi-asserted-by":"crossref","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol. (Chicago, Ill. 1960) 121, 1684\u201394 (2003).","DOI":"10.1001\/archopht.121.12.1684"},{"key":"BFsrep27082_CR12","doi-asserted-by":"crossref","unstructured":"Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch. Ophthalmol. (Chicago, Ill. 1960) 119, 1110\u20138 (2001).","DOI":"10.1001\/archopht.119.8.1110"},{"key":"BFsrep27082_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","volume":"116","author":"T Sato","year":"2009","unstructured":"Sato, T., Kusaka, S., Shimojo, H. & Fujikado, T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116, 1599\u2013603 (2009).","journal-title":"Ophthalmology"},{"key":"BFsrep27082_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","volume":"115","author":"K Sonmez","year":"2008","unstructured":"Sonmez, K., Drenser, K. A., Capone, A. & Trese, M. T. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115, 1065\u20131070. e1 (2008).","journal-title":"Ophthalmology"},{"key":"BFsrep27082_CR15","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4103\/0366-6999.164937","volume":"128","author":"M Zhao","year":"2015","unstructured":"Zhao, M. et al. Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF 165 b Isoform in the Vitreous of Patients with Retinopathy of Prematurity. Chin. Med. J. (Engl). 128, 2505\u20139 (2015).","journal-title":"Chin. Med. J. (Engl)."},{"key":"BFsrep27082_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A., Kennedy, K. A. & Chuang, A. Z. Efficacy of intravitreal bevacizumab for stage 3\u2009+\u2009retinopathy of prematurity. N. Engl. J. Med. 364, 603\u201315 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep27082_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","volume":"155","author":"BC Harder","year":"2013","unstructured":"Harder, B. C. et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am. J. Ophthalmol. 155, 1119\u20131124. e1 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"BFsrep27082_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck, M. M. et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 132, 1327\u201333 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"BFsrep27082_CR19","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery, R. L. et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br. J. Ophthalmol. 98, 1636\u201341 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"BFsrep27082_CR20","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","volume":"90","author":"AM Carneiro","year":"2012","unstructured":"Carneiro, A. M. et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 90, e25\u201330 (2012).","journal-title":"Acta Ophthalmol."},{"key":"BFsrep27082_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/bjophthalmol-2012-302451","volume":"97","author":"C Zehetner","year":"2013","unstructured":"Zehetner, C., Kirchmair, R., Huber, S., Kralinger, M. T. & Kieselbach, G. F. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br. J. Ophthalmol. 97, 454\u20139 (2013).","journal-title":"Br. J. Ophthalmol."},{"key":"BFsrep27082_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","volume":"97","author":"MAM Castellanos","year":"2013","unstructured":"Castellanos, M. A. M., Schwartz, S., Garc\u00eda-Aguirre, G. & Quiroz-Mercado, H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br. J. Ophthalmol. 97, 816\u20139 (2013).","journal-title":"Br. J. Ophthalmol."},{"key":"BFsrep27082_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"S-N Chen","year":"2015","unstructured":"Chen, S.-N. et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina 35, 667\u201374 (2015).","journal-title":"Retina"},{"key":"BFsrep27082_CR24","first-page":"340","volume":"78","author":"MK Erol","year":"2015","unstructured":"Erol, M. K. et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq. Bras. Oftalmol. 78, 340\u20133 (2015).","journal-title":"Arq. Bras. Oftalmol."},{"key":"BFsrep27082_CR25","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster, R. et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 91, e74\u20135 (2013).","journal-title":"Acta Ophthalmol."},{"key":"BFsrep27082_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/0974-620X.106103","volume":"5","author":"C-J Lin","year":"2012","unstructured":"Lin, C.-J., Chen, S.-N. & Hwang, J.-F. Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity. Oman J. Ophthalmol. 5, 184\u20136 (2012).","journal-title":"Oman J. Ophthalmol."},{"key":"BFsrep27082_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000338623","volume":"3","author":"A Mota","year":"2012","unstructured":"Mota, A. et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep. Ophthalmol. 3, 136\u201341 (2012).","journal-title":"Case Rep. Ophthalmol."},{"key":"BFsrep27082_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","volume":"14","author":"SY Jang","year":"2010","unstructured":"Jang, S. Y., Choi, K. S. & Lee, S. J. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J. AAPOS 14, 457\u20139 (2010).","journal-title":"J. AAPOS"},{"key":"BFsrep27082_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong, R. K., Hubschman, S. & Tsui, I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35, 675\u201380 (2015).","journal-title":"Retina"},{"key":"BFsrep27082_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1542\/peds.2012-2996","volume":"131","author":"WM Fierson","year":"2013","unstructured":"Fierson, W. M. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131, 189\u201395 (2013).","journal-title":"Pediatrics"},{"key":"BFsrep27082_CR31","doi-asserted-by":"crossref","unstructured":"The International Classification of Retinopathy of Prematurity revisited. Arch. Ophthalmol. (Chicago, Ill. 1960) 123, 991\u20139 (2005).","DOI":"10.1001\/archopht.123.7.991"},{"key":"BFsrep27082_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","volume":"246","author":"S Honda","year":"2008","unstructured":"Honda, S., Hirabayashi, H., Tsukahara, Y. & Negi, A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefe\u2019s Arch. Clin. Exp. Ophthalmol.\u2009=\u2009Albr. von Graefes Arch. f\u00fcr Klin. und Exp. Ophthalmol. 246, 1061\u20133 (2008).","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol.\u2009=\u2009Albr. von Graefes Arch. f\u00fcr Klin. und Exp. Ophthalmol."},{"key":"BFsrep27082_CR33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","volume":"92","author":"S Kusaka","year":"2008","unstructured":"Kusaka, S. et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br. J. Ophthalmol. 92, 1450\u20135 (2008).","journal-title":"Br. J. Ophthalmol."},{"key":"BFsrep27082_CR34","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","volume":"35","author":"YR Hong","year":"2015","unstructured":"Hong, Y. R. et al. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina 35, 1772\u20137 (2015).","journal-title":"Retina"},{"key":"BFsrep27082_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"W-C Wu","year":"2015","unstructured":"Wu, W.-C. et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 133, 391\u20137 (2015).","journal-title":"JAMA Ophthalmol."},{"key":"BFsrep27082_CR36","first-page":"3165","volume":"52","author":"S-J Lee","year":"2011","unstructured":"Lee, S.-J., Kim, S.-Y., Yoo, B. chul, Kim, H. W. & Kim, Y. H. Plasma Level Of Vascular Endothelial Growth Factor In Retinopathy Of Prematurity After Intravitreal Injection Of Bevacizumab. Invest. Ophthalmol. Vis. Sci. 52, 3165 (2011).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFsrep27082_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ajo.2010.08.037","volume":"151","author":"T Sato","year":"2011","unstructured":"Sato, T., Shima, C. & Kusaka, S. Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity. Am. J. Ophthalmol. 151, 353\u20137. e1 (2011).","journal-title":"Am. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep27082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27082","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:10:54Z","timestamp":1672877454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep27082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,6,29]]}},"alternative-id":["BFsrep27082"],"URL":"https:\/\/doi.org\/10.1038\/srep27082","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]},"assertion":[{"value":"10 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27082"}}